Related Experiment Videos

Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific

H J Wallny1, K Deres, S Faath

  • 1Max-Planck-Institut für Biologie, Abteilung Immungenetik, Tübingen, Germany.

International Immunology
|October 1, 1992
PubMed

Insights

Researchers identified a mutated cellular gene product as the target antigen for cytotoxic T lymphocytes (CTLs) in a specific tumor. The study pinpointed the exact mutated peptide epitope responsible for the anti-tumor immune response.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Cytotoxic T lymphocytes (CTLs) play a crucial role in anti-tumor immunity.
  • Identifying tumor-specific antigens is vital for developing targeted cancer therapies.
  • Mutations in cellular genes can lead to the generation of neoantigens recognized by CTLs.

Purpose of the Study:

  • To identify the specific antigen recognized by H-2Kd-restricted CTLs against a mutagen-induced tumor.
  • To determine the precise epitope of the identified antigen.
  • To validate the naturally processed peptide presented by tumor cells.

Main Methods:

  • Utilized CTLs specific for a mutagen-induced antigen on DBA/2-derived tumor P815.
  • Employed synthetic peptides to map the epitope.
  • Predicted the naturally presented peptide using H-2Kd allele-specific peptide motifs.
  • Isolated and biochemically compared the natural peptide from tumor cells.

Main Results:

  • The target antigen was identified as a product of a normal cellular gene with a point mutation.
  • The CTL epitope was localized to an undecamer peptide containing the mutation.
  • The naturally presented nonamer peptide KYQAVTTTL was predicted and confirmed.
  • Approximately 100 copies of this nonapeptide are present per tumor cell.

Conclusions:

  • The study successfully identified a mutated self-peptide acting as a tumor-specific antigen.
  • This finding elucidates the molecular basis of CTL recognition of a mutagen-induced tumor antigen.
  • The identified peptide and its presentation mechanism provide insights for potential immunotherapeutic strategies.

Related Concept Videos